Biogen FY 2025 earnings snapshot

Biogen (BIIB) has wrapped up FY 2025 with Q4 revenue of US$2,279.4 million and a basic EPS loss of US$0.33, as the market weighs these numbers against already softening profitability. Over the past six quarters, revenue has moved from US$2,465.8 million in Q3 2024 to a peak of US$2,645.5 million in Q2 2025 before landing at US$2,279.4 million in Q4 2025. Quarterly EPS has ranged from US$2.67 in Q3 2024 up to US$4.33 in Q2 2025 before turning negative in the latest quarter. With a trailing 12 month net profit margin of 13.1% compared with 16.9% in the prior year and a large one off loss weighing on the numbers, this set of results puts profitability quality and margin resilience firmly in focus for investors.

See our full analysis for Biogen.

With the headline figures on the table, the next step is to see how these results line up with the widely followed bull and bear narratives around Biogen, and where the data pushes back on the market stories you hear most often.

US$986.1m one off loss distorts a US$1.3b profit base

• On a trailing basis Biogen earned US$1.3b of net income excluding extra items over the last 12 months, but that period also includes a one off loss of US$986.1m that weighs on the 13.1% net margin compared with 16.9% the prior year.
• What stands out for a cautious, more bearish view is that five year trailing earnings have fallen about 14.8% per year, and even in this latest year Biogen moved from quarterly net income of US$634.8m in Q2 2025 to a loss of US$48.9m in Q4, which critics point to as evidence that profit quality has been under pressure.
  • Those bears often highlight the margin step down from 16.9% to 13.1% and the Q4 basic EPS swing from US$4.33 in Q2 to a loss of US$0.33 as signals that profitability has been volatile.
  • The sequence of quarterly net income, from US$388.5m in Q3 2024 to US$266.7m in Q4 2024 and then to US$240.5m in Q1 2025 before the Q4 2025 loss, is used to argue that the recent profit trend has not yet settled into a clear recovery.

Over the last year those bumps in profit and the one off loss have given bears plenty to talk about, and they may see this earnings stretch as a stress test for Biogen’s margin resilience. 🐻 Biogen Bear Case

Revenue steady near US$9.9b while margins do more of the work

• Trailing 12 month revenue sits at US$9.9b compared with US$9.7b a year earlier, while the net profit margin over that same trailing window eased from 16.9% to 13.1%, and revenue is expected to decline around 0.7% per year over the next three years even as earnings are forecast to grow about 7.8% per year.
• Supporters with a more bullish angle often argue that if earnings are forecast to grow roughly 7.8% a year while revenue is expected to slip slightly, then the story is more about getting better returns from roughly the same US$9.9b sales base, although the recent margin move and Q4 2025 loss show that execution on costs and mix has to do the heavy lifting.
  • The contrast between a forecast earnings growth rate of about 7.8% and a revenue decline of 0.7% a year suggests those bulls are leaning on efficiency and margin rebuild more than on top line expansion.
  • At the same time, the fact that trailing margins are currently 13.1% instead of the prior 16.9% gives bears numerical backing when they say that the path to those forecasts is not yet visible in the reported numbers.

P/E in line with biotech while DCF fair value sits higher

• Biogen trades at a P/E of 22.8x, roughly matching the US biotech industry average of 22.8x and sitting slightly above the 21.2x peer average, yet the current share price of US$201.18 is about 48.2% below a stated DCF fair value of US$388.36.
• What is interesting for valuation focused investors is that the P/E being similar to the industry, despite the DCF fair value sitting almost twice the current price, creates a split narrative where one camp points to the large 48.2% gap to DCF while others stick with the idea that a sector average multiple combined with a 13.1% trailing margin and a US$986.1m one off loss does not obviously argue for a premium.
  • Supporters of the DCF case point to the US$1.3b trailing net income excluding extra items and the forecast 7.8% annual earnings growth as ingredients that can justify a higher fair value than today’s P/E multiple signals.
  • On the other hand, investors who lean toward the P/E comparison view the in line 22.8x multiple and lower margin versus the prior year as reasons to treat that DCF number as optimistic until reported profitability tracks closer to the forecasts.

If you want to see

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Biogen's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

See What Else Is Out There

Biogen’s recent one off loss, softer 13.1% net margin and swing to a Q4 loss all flag that earnings quality and consistency are under pressure.

If that volatility makes you want steadier fundamentals, check out 82 resilient stocks with low risk scores to quickly find companies where earnings and balance sheets look more resilient right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.